Embecta raised its fiscal 2026 adjusted earnings per share guidance to a range of $1.80 to $1.90, up from the prior $1.55 to $1.75, while also lifting its adjusted operating margin forecast to 23.5% to 24%. The company reaffirmed its full-year revenue guidance of $1.015 billion to $1.035 billion. For the third quarter, Embecta reported total revenue of approximately $272 million, with adjusted gross margin of 58.2% and adjusted operating margin of 25.5%. The improved margin outlook reflects cost controls and optimization efforts expected to yield further annualized benefits in 2027. The quarter also included the closing of the Owen Mumford acquisition, which broadens Embecta's product offerings into pharma services and auto-injectors.
Embecta CorpEmbecta raised FY2026 EPS and margin guidance, reflecting improved profitability outlook.